drug · small molecule
giredestrant
pre_registrationupdated 3mo agoby Genentech Inc🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
indications
indications
Breast Cancer
targets
Estrogen receptor
all catalysts(0)
nothing on the calendar yet
Trials studying giredestrant
- phase2A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- phase3A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- phase2A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
- phase1A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
- phase3A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- phase2A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
News(6)
- Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onRoche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…biospace · 19d ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 3mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 3mo ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 3mo ago
- Roche, facing biosimilar threats, puts faith in new cancer and obesity drugsOn a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.biopharma_dive · 3mo ago
- Roche says its investigational breast cancer pill could outsell HerceptinRoche still has high sales hopes for its breast cancer pill giredestrant despite the drug’s failure in a first-line trial earlier this year. CEO Thomas Schinecker said Thursday that the drug could ...endpoints · 3mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that